Logo image of BNTX

BIONTECH SE-ADR (BNTX) Stock Fundamental Analysis

NASDAQ:BNTX - Nasdaq - US09075V1026 - ADR - Currency: USD

112.89  -1.03 (-0.9%)

After market: 112.89 0 (0%)

Fundamental Rating

3

Taking everything into account, BNTX scores 3 out of 10 in our fundamental rating. BNTX was compared to 558 industry peers in the Biotechnology industry. BNTX has an average financial health and profitability rating. BNTX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year BNTX has reported negative net income.
BNTX had a positive operating cash flow in the past year.
Of the past 5 years BNTX 4 years were profitable.
BNTX had a positive operating cash flow in 4 of the past 5 years.
BNTX Yearly Net Income VS EBIT VS OCF VS FCFBNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

With an excellent Return On Assets value of -2.95%, BNTX belongs to the best of the industry, outperforming 88.97% of the companies in the same industry.
BNTX has a better Return On Equity (-3.43%) than 90.75% of its industry peers.
Industry RankSector Rank
ROA -2.95%
ROE -3.43%
ROIC N/A
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
BNTX Yearly ROA, ROE, ROICBNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 100 150

1.3 Margins

Looking at the Gross Margin, with a value of 84.90%, BNTX belongs to the top of the industry, outperforming 88.26% of the companies in the same industry.
In the last couple of years the Gross Margin of BNTX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BNTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
BNTX Yearly Profit, Operating, Gross MarginsBNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

5

2. Health

2.1 Basic Checks

BNTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BNTX has more shares outstanding
Compared to 5 years ago, BNTX has more shares outstanding
The debt/assets ratio for BNTX is higher compared to a year ago.
BNTX Yearly Shares OutstandingBNTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BNTX Yearly Total Debt VS Total AssetsBNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

An Altman-Z score of 6.48 indicates that BNTX is not in any danger for bankruptcy at the moment.
BNTX has a Altman-Z score of 6.48. This is amongst the best in the industry. BNTX outperforms 80.96% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that BNTX is not too dependend on debt financing.
BNTX has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: BNTX outperforms 42.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 6.48
ROIC/WACCN/A
WACC7.18%
BNTX Yearly LT Debt VS Equity VS FCFBNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

A Current Ratio of 7.45 indicates that BNTX has no problem at all paying its short term obligations.
BNTX has a Current ratio of 7.45. This is in the better half of the industry: BNTX outperforms 68.33% of its industry peers.
BNTX has a Quick Ratio of 7.34. This indicates that BNTX is financially healthy and has no problem in meeting its short term obligations.
BNTX has a Quick ratio of 7.34. This is in the better half of the industry: BNTX outperforms 67.79% of its industry peers.
Industry RankSector Rank
Current Ratio 7.45
Quick Ratio 7.34
BNTX Yearly Current Assets VS Current LiabilitesBNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

More info and screens

4

3. Growth

3.1 Past

BNTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -780.85%.
BNTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -27.96%.
BNTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 90.73% yearly.
EPS 1Y (TTM)-780.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.06%
Revenue 1Y (TTM)-27.96%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%-2.56%

3.2 Future

Based on estimates for the next years, BNTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.79% on average per year.
Based on estimates for the next years, BNTX will show a small growth in Revenue. The Revenue will grow by 3.67% on average per year.
EPS Next Y-90.57%
EPS Next 2Y-30.37%
EPS Next 3Y-23.38%
EPS Next 5Y9.79%
Revenue Next Year-22.11%
Revenue Next 2Y-8.03%
Revenue Next 3Y-5.59%
Revenue Next 5Y3.67%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BNTX Yearly Revenue VS EstimatesBNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
BNTX Yearly EPS VS EstimatesBNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20 30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BNTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BNTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNTX Price Earnings VS Forward Price EarningsBNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNTX Per share dataBNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

A cheap valuation may be justified as BNTX's earnings are expected to decrease with -23.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.37%
EPS Next 3Y-23.38%

More info and screens

0

5. Dividend

5.1 Amount

BNTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONTECH SE-ADR

NASDAQ:BNTX (7/11/2025, 8:00:02 PM)

After market: 112.89 0 (0%)

112.89

-1.03 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners22.49%
Inst Owner Change0.07%
Ins Owners2.11%
Ins Owner ChangeN/A
Market Cap27.14B
Analysts80
Price Target136.64 (21.04%)
Short Float %6.81%
Short Ratio5.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)188.14%
Min EPS beat(2)150.91%
Max EPS beat(2)225.36%
EPS beat(4)2
Avg EPS beat(4)73.79%
Min EPS beat(4)-62.82%
Max EPS beat(4)225.36%
EPS beat(8)5
Avg EPS beat(8)298.37%
EPS beat(12)8
Avg EPS beat(12)207.85%
EPS beat(16)12
Avg EPS beat(16)165.24%
Revenue beat(2)2
Avg Revenue beat(2)57.27%
Min Revenue beat(2)6.92%
Max Revenue beat(2)107.62%
Revenue beat(4)2
Avg Revenue beat(4)11.13%
Min Revenue beat(4)-56.98%
Max Revenue beat(4)107.62%
Revenue beat(8)2
Avg Revenue beat(8)-8.3%
Revenue beat(12)5
Avg Revenue beat(12)2.28%
Revenue beat(16)9
Avg Revenue beat(16)11.05%
PT rev (1m)1.4%
PT rev (3m)-1.72%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.96%
EPS NY rev (3m)-7.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)11.11%
Revenue NY rev (1m)1.74%
Revenue NY rev (3m)-1.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.44
P/FCF N/A
P/OCF 111.84
P/B 1.2
P/tB 1.27
EV/EBITDA N/A
EPS(TTM)-3.74
EYN/A
EPS(NY)-5.52
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)1.01
OCFY0.89%
SpS13.37
BVpS94.34
TBVpS88.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.95%
ROE -3.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.9%
FCFM N/A
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
F-Score3
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 151.78%
Cap/Sales 16.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.45
Quick Ratio 7.34
Altman-Z 6.48
F-Score3
WACC7.18%
ROIC/WACCN/A
Cap/Depr(3y)277.19%
Cap/Depr(5y)250.97%
Cap/Sales(3y)12.34%
Cap/Sales(5y)11.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-780.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.06%
EPS Next Y-90.57%
EPS Next 2Y-30.37%
EPS Next 3Y-23.38%
EPS Next 5Y9.79%
Revenue 1Y (TTM)-27.96%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%-2.56%
Revenue Next Year-22.11%
Revenue Next 2Y-8.03%
Revenue Next 3Y-5.59%
Revenue Next 5Y3.67%
EBIT growth 1Y-232.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.91%
EBIT Next 3Y-7.6%
EBIT Next 5Y21.39%
FCF growth 1Y-105.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-96.13%
OCF growth 3Y-38.43%
OCF growth 5YN/A